Initial Testing (Stage 1) of the Polo-Like Kinase Inhibitor Volasertib (BI 6727), by the Pediatric Preclinical Testing Program

BACKGROUND: Volasertib (BI 6727) is a potent inhibitor of Polo-like kinase 1 (Plk1), that is overexpressed in several childhood cancers and cell lines. Because of its novel mechanism of action, volasertib was evaluated through the PPTP. PROCEDURES: Volasertib was tested against the PPTP in vitro cel...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Pediatr Blood Cancer
Autores principales: Gorlick, Richard, Kolb, E. Anders, Keir, Stephen T., Maris, John M., Reynolds, C. Patrick, Kang, Min H., Carol, Hernan, Lock, Richard, Billups, Catherine A., Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2013
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4241497/
https://ncbi.nlm.nih.gov/pubmed/23956067
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24616
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares